Variations in cancer centers’ use of cytology for the diagnosis of unresectable pancreatic cancer in the National Cancer Data Base

Abstract

BACKGROUND:Cytology is an accurate, safe, cost-effective, and guideline-recommended method for pancreatic cancer diagnosis, particularly for unresectable disease. However, to the authors' knowledge, the frequency and determinants of its use have not been described to date. The current study examined patterns of cytological diagnosis among patients with unresectable pancreatic cancer by treatment facility type and by patient characteristics. METHODS: The prevalence of definitive cytological diagnosis (cytology only, without confirmatory histology) versus histological diagnosis (with or without accompanying cytology) was examined in National Cancer Data Base records of 13,657 patients diagnosed with unresectable (American Joint Committee on Cancer stages III and IV) pancreatic cancer in 2011 and 2012 who did not undergo surgical treatment (mode of diagnosis could not be ascertained for surgical patients). Associations between definitive cytological diagnosis and patient and facility characteristics were assessed using multivariable marginal logistic regression models and expressed as odds ratios (OR) and 95% confidence intervals (95% CIs). RESULTS: Overall, 26.8% of unresectable pancreatic cancer cases were definitively diagnosed with cytology. The prevalence of cytological diagnosis ranged from 16.5% in community cancer programs and 22.6% in comprehensive community cancer programs to 31.3% in academic/teaching/research cancer programs and 43.2% in National Cancer Institute-designated cancer programs (P<.001). Compared with patients diagnosed in National Cancer Institute-designated cancer programs, those from community cancer programs (OR, 0.29; 95% CI, 0.20-0.42), comprehensive community cancer programs (OR, 0.42; 95% CI, 0.31-0.59), and academic/teaching/research cancer programs (OR, 0.60; 95% CI, 0.43-0.84) had lower odds of being diagnosed with cytology. CONCLUSIONS: Greater than 25% of unresectable pancreatic cancers were diagnosed definitively with cytology, with wide variation in its use by facility type, suggesting opportunities for quality improvement interventions that increase the use of cytology. Cancer Cytopathol 2016;124:791-800.

Trends in Diagnosis of Gleason Score 2 Through 4 Prostate Cancer in the National Cancer Database, 1990–2013

“…Our recent analyses of NCDB records also showed significant variations by facility category, and among facilities within each category, in the cytologic diagnosis of small cell lung cancer and pancreatic cancer, which suggest a potential application of such analyses to improving collection of pulmonary and pancreatic specimens by pulmonologists, gastroenterologists, and radiologists, as well as improving interpretation of these specimens by pathologists. 35,36 Registry data are increasingly being used for clinical quality monitoring and improvement. Although this approach is not a panacea for pathology quality monitoring and improvement, we conclude that it can nonetheless make a significant contribution.…”

Cancer Cytopathology: 20 years of advancing the field of pancreaticobiliary cytopathology

“…Even autopsies can be performed using FNA, which can be enormously helpful in limited and restricted cases . The use of cytology specimens for definitive patient care and entry into clinical trials in not consistent throughout the country, but that will surely change in the next 20 years. The past 20 years have highlighted just how powerful a few cells from a tumor can be.…”